LIFE News and Press, aTyr Pharma Inc. From 06/21/21

Three-Year Endorsement Agreement Secured with Anthony Joshua OBE Heavyweight Champion of the World and Olympic Gold Medallist to Become Key Shareholder LONDON, UK / ACCESSWIRE / June 21, 2021 / Love Hemp Group PLC (AQSE:LIFE)(OTCQB:WRHLF) , one of the UK's leading CBD and hemp produ...

Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2. aNRP2-14 blocks Semaphorin 3F/NRP2 signaling pathways which are implicated in immune-mediated diseases. SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- aT...

LONDON, ENGLAND / ACCESSWIRE / June 9, 2021 / Love Hemp Group PLC (AQSE:LIFE) (OTCQB:WRHLF) , one of the UK's leading CBD and Hemp product suppliers, announces the issue of warrants and equity by the Company. Issue of warrants The Company has issued 15,746,325 warrants with an exercise pr...

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Sara Zaknoen, M.D., to the company’s Board o...

SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will present a poster and participate in a live Q&A sessio...

The following slide deck was published by aTyr Pharma, Inc. in conjunction with this event. For further details see: aTyr Pharma Investor Presentation - Slideshow

aTyr Pharma, Inc. (LIFE) Q1 2021 Earnings Conference Call May 12, 2021 05:00 PM ET Company Participants Ashlee Dunston - Director, IR and Corporate Communications Sanjay Shukla - President and CEO Jill Broadfoot - CFO Leslie Nangle - VP, Research Conference Call Participants Emanuela Branchet...

aTyr Pharma (LIFE): Q1 GAAP EPS of -$0.51 misses by $0.19.Ended the quarter with $50.6 million in cash, cash equivalents and investments.Shares +21%.Press Release For further details see: aTyr Pharma EPS misses by $0.19

Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter. Preclinical data for IND candidate ATYR2810 showed anti-tumor effects in models of TNBC and NSCLC. Bispecific antibody project with subsidiary Pangu BioPharma achieve...

SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company’s Hong Kong subsidiary, Pangu BioPharma Limite...